Braveheart Investment Group updated the market on progress with the Pharm2Farm (P2F) antiviral surgical mask project on Friday.
The AIM-traded firm said P2F had developed a coating for textiles which incorporated its proprietary nanoparticles, to give textiles long lasting virucidal properties.
It said the first application of the technology was to coat a fabric layer in surgical masks and produce a certified antiviral, including Covid-19 and influenza, mask for use by both healthcare professionals and the public.
Pharm2farm uses a patented process for producing and functionalising nanoparticles for various applications including human, animal and crop health. Pharm2farm is a wholly owned subsidiary of Remote Monitored Systems (LON:RMS).